ProKidney Corp.

NASDAQ:PROK

Biotechnology

Healthcare
$1.04 +0.86%

+$0.02 today

Market cap
$349.70M
Beta
1.70
P/E (TTM)
-3.3
EPS (TTM)
-$0.53
52W Low $0.54High $7.13

Volume 1.80M

Average 0.96M

PROK Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

ProKidney Corp.NASDAQ: PROK

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $4.95M fell 22.9% year over year, ahead of the -38.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 13.3% from the prior quarter. Over 3 fiscal years it compounded at -30.2% a year.

Context

  • Stock-based compensation amounted to 2837.2% of revenue in FY2025, down 35810.2 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -22.9% holds above the trailing-twelve-month pace of -38.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.95M-13.3% QoQ
Last fiscal yearDec 2025
$25.34M-13.7% YoY
LTMMar 2026
$17.19M-38.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.9%——
1 year-13.7%——
3-year CAGR-30.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
25.34M USD
Year-over-year change
-13.7%
4-year CAGR
+145.4%

Stock-Based Compensation vs competitors

How PROK compares with its peers on the latest reported figures

  • PROK's LTM Mar 2026 stock-based compensation of $17.19M is the 4th largest of the 7 companies compared; the peer median is $11.53M.
  • Its year-over-year change of -38.8% is the lowest of 6, against a peer median of +21.9%.
  • Stock-based compensation amounts to 1933.5% of revenue for PROK, versus a peer median of 11.9%.
PROK Competitors Peer median
Stock-Based Compensation for PROK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TVTXTravere Therapeutics, Inc.LTM Sep 2026$72.84M +70.9%+5.6%11.2%
ARDXArdelyx, Inc.LTM Mar 2026$51.03M +21.9%+65.8%11.9%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$20.28M +92.0%+34.5%101.4%
PROKProKidney Corp.LTM Mar 2026$17.19M -38.8%-30.2%1933.5%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$2.79M +13.0%+36.8%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$2.1M -12.1%+36.1%—
MENSJyong Biotech Ltd. Ordinary SharesLTM Dec 2024$0 ———
Peer median (excluding PROK) $11.53M+21.9%+36.1%11.9%

Competitors are the stored peer set for PROK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(55.15M)(148.14M)(135.45M)(163.34M)(151.61M)
Depreciation & Amortization1.98M3.04M3.85M5.43M6.58M
Deferred Income Tax00000
Stock-Based Compensation699K74.47M30.85M29.37M25.34M
Change in Working Capital2.16M(6.46M)16.67M3.96M1.28M
Accounts Receivables00(1.38M)(1.07M)1.32M
Inventory00000
Accounts Payables5K494K11.64M11.59M(5.92M)
Other Working Capital2.16M(6.95M)6.41M(6.56M)5.88M
Other Non-Cash Items00(6M)(1.78M)(1.7M)
Operating Cash Flow(50.3M)(77.09M)(90.07M)(126.35M)(120.12M)
Capital Expenditures(5.19M)(1.85M)(34.2M)(29.51M)(15.2M)
Acquisitions (Net)1K108K0018.22M
Purchases of Investments00(471.6M)(324.02M)(217.08M)
Sales of Investments00175.82M373.95M318.02M
Other Investing Activities00000
Investing Cash Flow(5.19M)(1.74M)(329.98M)20.41M103.97M
Debt Repayment(30K)(32K)(52K)(54K)(26K)
Common Stock Issued71.5M6.05M0144.32M25.6M
Common Stock Repurchased00(9.5M)00
Dividends Paid00000
Other Financing Activities0542.5M0140K0
Financing Cash Flow71.47M548.52M(9.55M)144.41M25.57M
Effect of Forex Changes00000
Net Change in Cash15.98M469.69M(429.6M)38.47M9.42M
Free Cash Flow(55.49M)(78.94M)(124.27M)(155.86M)(135.31M)

ProKidney Corp.

NASDAQ:PROK

Intrinsic Alpha fair value

Locked

Current Price

$1.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.